Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cytokinetics (CYTK)

Cytokinetics (CYTK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,029,142
  • Shares Outstanding, K 122,265
  • Annual Sales, $ 18,470 K
  • Annual Income, $ -589,530 K
  • EBIT $ -573 M
  • EBITDA $ -563 M
  • 60-Month Beta 0.58
  • Price/Sales 440.38
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 89.11% (+6.13%)
  • Historical Volatility 39.48%
  • IV Percentile 96%
  • IV Rank 66.93%
  • IV High 110.92% on 04/09/25
  • IV Low 44.98% on 01/22/25
  • Expected Move (DTE 13) 6.66 (10.15%)
  • Put/Call Vol Ratio 0.51
  • Today's Volume 616
  • Volume Avg (30-Day) 2,100
  • Put/Call OI Ratio 0.21
  • Today's Open Interest 111,564
  • Open Int (30-Day) 113,689
  • Expected Range 59.01 to 72.33

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.48
  • Number of Estimates 10
  • High Estimate -0.20
  • Low Estimate -2.14
  • Prior Year -1.26
  • Growth Rate Est. (year over year) -17.46%

Price Performance

See More
Period Period Low Period High Performance
1-Month
58.05 +13.13%
on 11/06/25
69.33 -5.28%
on 11/28/25
+6.48 (+10.95%)
since 11/05/25
3-Month
47.22 +39.07%
on 09/25/25
69.33 -5.28%
on 11/28/25
+12.66 (+23.88%)
since 09/05/25
52-Week
29.31 +124.05%
on 05/15/25
69.33 -5.28%
on 11/28/25
+15.27 (+30.30%)
since 12/05/24

Most Recent Stories

More News
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

SOUTH SAN FRANCISCO, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on November 15, 2025 it granted stock options to purchase 87,297 restricted...

CYTK : 65.67 (-1.31%)
CYTK Deadline: CYTK Investors Have Opportunity to Lead Cytokinetics, Inc. Securities Fraud Lawsuit

NEW YORK , Nov. 17, 2025 /PRNewswire/ --

CYTK : 65.67 (-1.31%)
CYTK LAWSUIT ALERT: Levi & Korsinsky Notifies Cytokinetics, Incorporated Investors - Lead Plaintiff Deadline November 17, 2025

New York, New York--(Newsfile Corp. - November 17, 2025) - If you suffered a loss on your Cytokinetics, Incorporated (NASDAQ: CYTK) investment and want to learn about a potential recovery under the federal...

CYTK : 65.67 (-1.31%)
CYTK FINAL DEADLINE: Faruqi & Faruqi, LLP Announces that Cytokinetics Investors Have Opportunity to Lead Class Action Lawsuit

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Cytokinetics To Contact Him Directly To Discuss Their...

CYTK : 65.67 (-1.31%)
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Cytokinetics, Incorporated (CYTK) Shareholders

NEW YORK , Nov. 17, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cytokinetics, Incorporated (NASDAQ: CYTK).

CYTK : 65.67 (-1.31%)
Cytokinetics Supports American Heart Association Initiative to Improve Care for People Living With Hypertrophic Cardiomyopathy

System of Care to Advance Care for the Most Commonly Inherited Heart Disease SOUTH SAN FRANCISCO, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) --   Cytokinetics, Inc. (Nasdaq: CYTK) today announced its...

CYTK : 65.67 (-1.31%)
Cytokinetics 72 Hour Deadline Alert: Former Louisiana Attorney General And Kahn Swick & Foti, LLC Remind Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Cytokinetics, Incorporated - CYTK

Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until November 17, 2025 ...

CYTK : 65.67 (-1.31%)
Cytokinetics, Incorporated (CYTK) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

BENSALEM, Pa. , Nov. 14, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action...

CYTK : 65.67 (-1.31%)
CYTK DEADLINE: Faruqi & Faruqi Reminds Cytokinetics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 17, 2025 - CYTK

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Cytokinetics To Contact Him Directly To Discuss Their Options

CYTK : 65.67 (-1.31%)
Cytokinetics, Incorporated Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before November 17, 2025 to Discuss Your Rights - CYTK

NEW YORK , Nov. 14, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cytokinetics, Incorporated ("Cytokinetics" or the "Company") (NASDAQ: CYTK) of a class action securities...

CYTK : 65.67 (-1.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology...

See More

Key Turning Points

3rd Resistance Point 68.22
2nd Resistance Point 67.58
1st Resistance Point 66.63
Last Price 65.67
1st Support Level 65.04
2nd Support Level 64.40
3rd Support Level 63.45

See More

52-Week High 69.33
Last Price 65.67
Fibonacci 61.8% 54.04
Fibonacci 50% 49.32
Fibonacci 38.2% 44.60
52-Week Low 29.31

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar